Literature DB >> 6093251

Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS.

H J Alter, J W Eichberg, H Masur, W C Saxinger, R Gallo, A M Macher, H C Lane, A S Fauci.   

Abstract

Two of three chimpanzees given plasma from patients with acquired immune deficiency syndrome (AIDS) or pre-AIDS showed serum antibodies to type III human T-cell leukemia virus (HTLV-III) 10 to 12 weeks after transfusion. One animal also developed lymphadenopathy, transient depression of the ratio of T4 to T8 lymphocytes, and impaired blastogenic responses. No opportunistic infections occurred. Adenopathy persisted for 32 weeks, and antibody to HTLV-III persisted for at least 48 weeks. This transmission of HTLV-III by lymphocyte-poor plasma confirms the potential risk of such plasma or plasma derivatives to recipients. The susceptibility of the chimpanzee to HTLV-III infection and the ability to simulate the human lymphadenopathy syndrome in this animal makes it a valuable model for further study of AIDS.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093251     DOI: 10.1126/science.6093251

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  74 in total

1.  Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.

Authors:  T Beaumont; S Broersen; A van Nuenen; H G Huisman; A M de Roda Husman; J L Heeney; H Schuitemaker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells.

Authors:  R Shibata; M Kawamura; H Sakai; M Hayami; A Ishimoto; A Adachi
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

3.  RNA-mediated transfer of cellular immunity to a synthetic env antigen of the human immunodeficiency virus (HIV-1).

Authors:  G A Passos Júnior; F L de Lucca
Journal:  Mol Cell Biochem       Date:  1991-11-13       Impact factor: 3.396

4.  Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4.

Authors:  R Kikukawa; Y Koyanagi; S Harada; N Kobayashi; M Hatanaka; N Yamamoto
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

5.  Simultaneous isolation of simian foamy virus and HTLV-III/LAV from chimpanzee lymphocytes following HTLV-III or LAV inoculation.

Authors:  P L Nara; W G Robey; L O Arthur; M A Gonda; D M Asher; R Yanagihara; C J Gibbs; D C Gajdusek; P J Fischinger
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

Review 6.  Study of the T cell receptor repertoire in viral immunodeficiency disease.

Authors:  C Ciurli; R P Sékaly; H Soudeyns
Journal:  Springer Semin Immunopathol       Date:  1996

7.  Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.

Authors:  L O Arthur; J W Bess; D J Waters; S W Pyle; J C Kelliher; P L Nara; K Krohn; W G Robey; A J Langlois; R C Gallo
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

8.  Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity.

Authors:  B D Jamieson; G M Aldrovandi; V Planelles; J B Jowett; L Gao; L M Bloch; I S Chen; J A Zack
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Serological, biological, and molecular characterization of New Zealand white rabbits infected by intraperitoneal inoculation with cell-free human immunodeficiency virus.

Authors:  S Reina; P Markham; E Gard; F Rayed; M Reitz; R C Gallo; O E Varnier
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

10.  Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors.

Authors:  Beatriz Pacheco; Stephane Basmaciogullari; Jason A Labonte; Shi-Hua Xiang; Joseph Sodroski
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.